514 related articles for article (PubMed ID: 31440799)
1. EANM procedure guidelines for radionuclide therapy with
Kratochwil C; Fendler WP; Eiber M; Baum R; Bozkurt MF; Czernin J; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen W; Rahbar K; Schöder H; Virgolini I; Wester HJ; Bodei L; Fanti S; Haberkorn U; Herrmann K
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2536-2544. PubMed ID: 31440799
[TBL] [Abstract][Full Text] [Related]
2. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
Ferdinandus J; Violet J; Sandhu S; Hofman MS
Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583
[TBL] [Abstract][Full Text] [Related]
4. Real-world Outcomes and Predictive Biomarkers for
Kafka M; Horninger A; di Santo G; Virgolini I; Neuwirt H; Unterrainer LM; Kunte SC; Deiss E; Paffenholz P; Heidenreich A; Rasul S; Einspieler H; Shariat SF; Rajwa P; Dozauer R; Tsaur I; Medlock E; Rölz N; Rausch S; la Fougère C; Trautwein N; Roesch MC; Merseburger AS; Zattoni F; Sepulcri M; Ladurner M; Bektic J; Gandaglia G; Horninger W; Heidegger I
Eur Urol Oncol; 2024 Jun; 7(3):421-429. PubMed ID: 37604763
[TBL] [Abstract][Full Text] [Related]
5.
Fendler WP; Rahbar K; Herrmann K; Kratochwil C; Eiber M
J Nucl Med; 2017 Aug; 58(8):1196-1200. PubMed ID: 28663195
[No Abstract] [Full Text] [Related]
6. Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with
Huang K; Schatka I; Rogasch JMM; Lindquist RL; De Santis M; Erber B; Radojewski P; Brenner W; Amthauer H
Ann Nucl Med; 2021 Mar; 35(3):314-320. PubMed ID: 33351172
[TBL] [Abstract][Full Text] [Related]
7. Lutetium
Emmett L; Willowson K; Violet J; Shin J; Blanksby A; Lee J
J Med Radiat Sci; 2017 Mar; 64(1):52-60. PubMed ID: 28303694
[TBL] [Abstract][Full Text] [Related]
8. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].
Ahmadzadehfar H; Albers P; Bockisch A; Boegemann M; Böhme C; Burchert W; Dietlein M; Drzezga A; Fabry U; Feldmann G; Heidenreich A; Heinzel A; Herrmann K; Heyll A; Höhling C; Kreuzer C; Laufer D; Mengel R; Mottaghy FM; Müller HW; Müller SC; Ost E; Rahbar K; Reifenhäuser W; Schäfers M; Schlenkhoff C; Schmidt M; Schmidt-Wolf I; Wildenhain C; Zimmer B; Essler M
Urologe A; 2018 Jun; 57(6):709-713. PubMed ID: 29671080
[TBL] [Abstract][Full Text] [Related]
9. [PSMA-targeted radioligand therapy in prostate cancer].
Heck MM; Retz M; Tauber R; Knorr K; Kratochwil C; Eiber M
Urologe A; 2017 Jan; 56(1):32-39. PubMed ID: 27885457
[TBL] [Abstract][Full Text] [Related]
10. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
[TBL] [Abstract][Full Text] [Related]
11. Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.
Inubushi M; Miura H; Kuji I; Ito K; Minamimoto R
Ann Nucl Med; 2020 Dec; 34(12):879-883. PubMed ID: 33175360
[TBL] [Abstract][Full Text] [Related]
12. Radioligand Therapy With
Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
[No Abstract] [Full Text] [Related]
13. Joint EANM/SNMMI procedure guideline for the use of
Kratochwil C; Fendler WP; Eiber M; Hofman MS; Emmett L; Calais J; Osborne JR; Iravani A; Koo P; Lindenberg L; Baum RP; Bozkurt MF; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen WJG; Rahbar K; Schoder H; Virgolini I; Bodei L; Fanti S; Haberkorn U; Hermann K
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2830-2845. PubMed ID: 37246997
[TBL] [Abstract][Full Text] [Related]
14. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
[TBL] [Abstract][Full Text] [Related]
15.
Cao J; Chen Y; Hu M; Zhang W
Ann Nucl Med; 2021 Aug; 35(8):861-870. PubMed ID: 34176105
[TBL] [Abstract][Full Text] [Related]
16. A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR).
Kryza D; Vinceneux A; Bidaux AS; Garin G; Tatu D; Cropet C; Badel JN; Perol D; Giraudet AL
BMC Cancer; 2024 Feb; 24(1):163. PubMed ID: 38302933
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
18. Early Prostate-Specific Antigen Changes and Clinical Outcome After
Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
[TBL] [Abstract][Full Text] [Related]
19. Adoption of Lutetium-
Flegar L; Thoduka SG; Librizzi D; Luster M; Zacharis A; Heers H; Eisenmenger N; Ahmadzadehfar H; Eiber M; Weber W; Groeben C; Huber J
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2188-2195. PubMed ID: 36826478
[TBL] [Abstract][Full Text] [Related]
20. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Satapathy S; Mittal BR; Sood A
Clin Nucl Med; 2020 Dec; 45(12):935-942. PubMed ID: 32956129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
